Search

Your search keyword '"Topouzoglou, Zoi"' showing total 6 results
Start Over Author "Topouzoglou, Zoi"
6 results on '"Topouzoglou, Zoi"'

2. Validation of the Revised International Prognostic Scoring System in 2582 Patients with Myelodysplastic Syndrome: A Multicenter Study By the Hellenic MDS Study Group

Author

Galanopoulos, Athanasios, primary, Kontos, Christos K., additional, Viniou, Nora-Athina, additional, Kotsianidis, Ioannis, additional, Pappa, Vassiliki, additional, Kourakli, Aleka, additional, Pouli, Anastasia, additional, Panayiotidis, Panayiotis, additional, Roussou, Paraskevi, additional, Zafeiropoulou, Kalliopi, additional, Karakatsanis, Stamatis, additional, Dimou, Maria, additional, Vardi, Anna, additional, Vassilakopoulos, Theodoros, additional, Tsokanas, Dimitris, additional, Hatzimichael, Eleftheria, additional, Megalakaki, Aikaterini, additional, Kaiafa, Georgia D, additional, Papoutselis, Menelaos Konstantinos, additional, Sioni, Anastasia, additional, Charchalakis, Nikolaos, additional, Bouronikou, Eleni, additional, Vassilopoulos, George, additional, Lazaris, Vasilios, additional, Spiliotopoulou, Maria, additional, Diamantopoulos, Panagiotis Theodorou, additional, Kontopidou, Flora, additional, Topouzoglou, Zoi, additional, Kalyva, Stamatina, additional, Papadaki, Helen A., additional, Hatzitolios, Apostolos I, additional, Anagnostopoulos, Achilles, additional, Briasoulis, Evangelos, additional, Anagnostopoulos, Nikolaos I., additional, and Symeonidis, Argiris S., additional

Published
2016
Full Text
View/download PDF

3. Dose Adjustment and Use of Alternative Eltrombopag Dosing Regimens for the Treatment of Patients with Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)

Author

Galanopoulos, Athanasios, primary, Bacarakos, Panagiotis, additional, Tsokanas, Dimitris, additional, Minakakis, Ilias, additional, Topouzoglou, Zoi, additional, Leveta, Georgia, additional, Marinakis, Theodore, additional, Papadaki, Christina, additional, Grigoraki, Vasiliki, additional, Griva-Kritikou, Elpiniki, additional, and Nikolaos, Anagnostopoulos I., additional

Published
2012
Full Text
View/download PDF

4. Prognosis of Lower Risk Patients with Myelodysplastic Syndromes without Isolated Del(5q) after Failure of Erythropoiesis-Stimulating Agents. a Multicenter Study By the Hellenic MDS Study Group

Author

Galanopoulos, Athanasios G., Kontos, Christos K., Symeonidis, Argiris, Kotsianidis, Ioannis, Kourakli, Alexandra, Pappa, Vassiliki, Tsiambalis, Thomas, Pouli, Anastasia, Panayiotidis, Panayiotis, Roussou, Paraskevi, Karakatsanis, Stamatis, Zafeiropoulou, Kalliopi, Dimou, Maria, Vassilakopoulos, Theodoros P., Vardi, Anna, Tsokanas, Dimitrios, Drakos, George, Eleftheria Hatzimichael, Megalakaki, Aikaterini, Repousis, Panagiotis, Kotsopoulou, Maria, Solomou, Elena E., Kaiafa, Georgia, Papoutselis, Menelaos Konstantinos, Sioni, Anastasia, Charchalakis, Nikolaos, Bouronikou, Eleni, Vassilopoulos, George, Lazaris, Vasileios, Galanopoulos, Athanasios, Diamantopoulos, Panagiotis Theodorou, Kontopidou, Flora, Topouzoglou, Zoi, Kalyva, Stamatina, Papadaki, Helen A., Hatzitolios, Apostolos, Anagnostopoulos, Achilles, Anagnostopoulos, Nikolaos, and Viniou, Nora-Athina

5. Azacytidine Failure Revisited: An Appraisal Based on Real Life Data from the MDS Registry of the Hellenic Myelodysplastic Syndrome Study Group (HMDS)

Author

Kotsianidis, Ioannis, Papageorgiou, Sotirios, Pappa, Vassiliki, Galanopoulos, Athanasios, Viniou, Nora-Athina, Kourakli, Alexandra, Vassilakopoulos, Theodoros, Papoutselis, Menelaos Konstantinos, Topouzoglou, Zoi, Diamantopoulos, Panagiotis Theodorou, Τsokanas, Dimitrios, and Symeonidis, Argiris

Abstract

Azacytidine (AZA) is the mainstay of treatment for high-risk MDS, but both primary and secondary AZA failure confers a grave prognosis. Given the limited availability and efficacy of subsequent treatment options the exact definition of AZA failure and the decision to discontinue AZA is of particular importance in everyday clinical practice. However, the current definition of AZA failure is rather obscure and often lumps together pathobiologically diverse disease states, as reflected by the highly heterogeneous outcome of patients who fail AZA (post-HMA model, Nazha A et al, 2016).

Published
2017
Full Text
View/download PDF

6. Prognosis of Lower Risk Patients with Myelodysplastic Syndromes without Isolated Del(5q) after Failure of Erythropoiesis-Stimulating Agents. a Multicenter Study By the Hellenic MDS Study Group

Author

Galanopoulos, Athanasios G., Kontos, Christos K., Symeonidis, Argiris, Kotsianidis, Ioannis, Kourakli, Alexandra, Pappa, Vassiliki, Tsiambalis, Thomas, Pouli, Anastasia, Panayiotidis, Panayiotis, Roussou, Paraskevi, Karakatsanis, Stamatis, Zafeiropoulou, Kalliopi, Dimou, Maria, Vassilakopoulos, Theodoros P., Vardi, Anna, Tsokanas, Dimitrios, Drakos, George, Hatzimichael, Eleftheria, Megalakaki, Aikaterini, Repousis, Panagiotis, Kotsopoulou, Maria, Solomou, Elena E., Kaiafa, Georgia, Papoutselis, Menelaos Konstantinos, Sioni, Anastasia, Charchalakis, Nikolaos, Bouronikou, Eleni, Vassilopoulos, George, Lazaris, Vasileios, Galanopoulos, Athanasios, Diamantopoulos, Panagiotis Theodorou, Kontopidou, Flora, Topouzoglou, Zoi, Kalyva, Stamatina, Papadaki, Helen A., Hatzitolios, Apostolos, Anagnostopoulos, Achilles, Anagnostopoulos, Nikolaos, and Viniou, Nora-Athina

Abstract

Most anemic non-del(5q) lower risk myelodyplastic syndromes (MDS) patients are treated with erythropoiesis stimulating agents (ESAs). Second-line treatments, including hypomethylating agents (HMA), lenalidomide (LEN) and other drugs, may be used after ESA failure in some countries, but their effect on disease progression, transformation to acute myeloid leukemia (AML), and overall survival (OS) is unknown. We analyzed MDS patients' outcome after primary or secondary failure of treatment with ESAs as a first-line treatment option.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results